Investment Thesis
Immunovant is a pre-commercial or early-stage biotech burning cash at an unsustainable rate, with operating losses of $505.4M against only $24.9M revenue. Despite strong 229% YoY revenue growth and excellent liquidity ($902.1M cash), the company is depleting reserves at ~$407.3M annually with no visible path to profitability, providing only ~2 years of runway at current burn rates.
Strengths
- Revenue growth of 229% YoY indicates successful early commercialization or product adoption
- Exceptional liquidity with $902.1M cash and 9.09x current ratio provides operational runway
- Debt-free balance sheet (0.00x debt/equity) eliminates financial distress risk near-term
Risks
- Operating losses of $505.4M with -2025.8% operating margin indicates severe unprofitability and unsustainable burn
- Cash burn of $407.3M annually will deplete reserves in approximately 2.2 years without profitability or financing
- Fundamental business model challenged: company burning 20x its revenue in operating costs with no clear profitability timeline
Key Metrics to Watch
- Quarterly revenue growth rate and gross margin expansion trajectory
- Operating cash burn rate trend and cash runway remaining
- Path to operating profitability or evidence of margin improvement trajectory
Financial Metrics
Revenue
24.9M
Net Income
-505.6M
EPS (Diluted)
$-2.77
Free Cash Flow
-407.3M
Total Assets
957.0M
Cash
902.1M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-2,025.8%
Net Margin
-2,026.6%
ROE
-59.3%
ROA
-52.8%
FCF Margin
-1,632.7%
Balance Sheet & Liquidity
Current Ratio
9.09x
Quick Ratio
9.09x
Debt/Equity
0.00x
Debt/Assets
10.9%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-22T07:37:14.376601 |
Data as of: 2026-03-31 |
Powered by Claude AI